BillionToOne vs CareDx
BLLN and CDNA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLLN and CDNA compare
BillionToOne is the larger company, worth 1.2 times as much as CareDx ($5.2B against $4.3B).
BillionToOne grew revenue faster over the last twelve months (71.9% versus 38.9% for CareDx).
CareDx keeps more of each dollar of sales as profit, with a net margin of 25.9% compared with 11.3% at BillionToOne.
CareDx scores higher on the StockData Score (12 against 11 for BillionToOne), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLLN | CDNA |
|---|---|---|
| Size and price | ||
| Market cap | $5.2B | $4.3B |
| Share price | $110.23 | $81.17 |
| Change, 1 year | 7.8% | 386% |
| Change, 5 years | – | 88.7% |
| Beta (5Y) | 0.04 | 1.52 |
| Employees | 713 | 765 |
| StockData Score | ||
| Total score | 11 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 34.0× |
| P/S | 11.9× | 8.6× (better) |
| P/B | 9.2× | 9.1× (better) |
| EV/EBITDA | 89.4× | 29.9× (better) |
| P/FCF | 153× | – |
| FCF yield | 0.65% | – |
| Fair value | – | $66.02 |
| Margin of safety | – | −22.9% |
| Growth | ||
| Revenue growth (TTM) | 71.9% (better) | 38.9% |
| Revenue growth, 5Y average | – | 14.6% |
| Net income growth (TTM) | – | 82.6% |
| Profitability | ||
| Gross margin | 71.4% | – |
| Operating margin | 10.2% | 23.4% (better) |
| Net margin | 11.3% | 25.9% (better) |
| FCF margin | 7.8% | – |
| Return on equity | 30.2% | 33.0% (better) |
| Return on invested capital | – | 69.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | 1655× | – |
| Current ratio | 11.25 (better) | 2.31 |
| Altman Z-score | 17.41 (better) | 15.36 |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 32.4% | 102% |
| Held by insiders | 55.7% | 4.8% |
| Insider net buying, 12 months | −$58.5M | −$18.1M (better) |
| Short interest, % of float | 14.2% | 14.4% |
Go deeper
- BLLN stock overview
- BLLN income statement
- BLLN valuation and score
- CDNA stock overview
- CDNA income statement
- CDNA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.